JP2000516098A - 短シャフトアデノウイルスファイバーおよびその用途 - Google Patents
短シャフトアデノウイルスファイバーおよびその用途Info
- Publication number
- JP2000516098A JP2000516098A JP10510960A JP51096098A JP2000516098A JP 2000516098 A JP2000516098 A JP 2000516098A JP 10510960 A JP10510960 A JP 10510960A JP 51096098 A JP51096098 A JP 51096098A JP 2000516098 A JP2000516098 A JP 2000516098A
- Authority
- JP
- Japan
- Prior art keywords
- adenovirus
- fiber
- binding
- cell
- short shaft
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70546—Integrin superfamily
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10321—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10345—Special targeting system for viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/14011—Baculoviridae
- C12N2710/14041—Use of virus, viral particle or viral elements as a vector
- C12N2710/14043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vectore
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/14011—Baculoviridae
- C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
- C12N2710/14141—Use of virus, viral particle or viral elements as a vector
- C12N2710/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
- C12N2810/40—Vectors comprising a peptide as targeting moiety, e.g. a synthetic peptide, from undefined source
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
- C12N2810/40—Vectors comprising a peptide as targeting moiety, e.g. a synthetic peptide, from undefined source
- C12N2810/405—Vectors comprising RGD peptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
- C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
- C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
- C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
- C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
- C12N2810/6009—Vectors comprising as targeting moiety peptide derived from defined protein from viruses dsDNA viruses
- C12N2810/6018—Adenoviridae
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
- C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
- C12N2810/80—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates
- C12N2810/85—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian
- C12N2810/855—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian from receptors; from cell surface antigens; from cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
- C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
- C12N2810/80—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates
- C12N2810/85—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian
- C12N2810/855—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian from receptors; from cell surface antigens; from cell surface determinants
- C12N2810/856—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian from receptors; from cell surface antigens; from cell surface determinants from integrins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
- C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
- C12N2810/80—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates
- C12N2810/85—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian
- C12N2810/859—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian from immunoglobulins
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Gastroenterology & Hepatology (AREA)
- Plant Pathology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Treatments For Attaching Organic Compounds To Fibrous Goods (AREA)
- Yarns And Mechanical Finishing Of Yarns Or Ropes (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.テール、シャフトおよびノブを含む短シャフトアデノウイルスファイバー。 2.該シャフト状物が約12個以下のβリピートを含む、請求の範囲1の短シャ フトアデノウイルスファイバー。 3.該シャフトがC血清群またはD血清群の血清型のものであり、該ノブがC血 清群またはD血清群の血清型のものである、請求の範囲1または2の短シャフト アデノウイルスファイバー。 4.該シャフトおよびノブが同じ血清型のものである、請求の範囲1〜3のいず れかの短シャフトアデノウイルスファイバー。 5.該シャフトが天然に存在するアデノウイルス中のテールに隣接するシャフト の部分を含む、請求の範囲1〜4のいずれかの短シャフトアデノウイルスファイ バー。 6.該短シャフトファイバーが非天然のアミノ酸配列を含む、請求の範囲1〜5 のいずれかの短シャフトアデノウイルスファイバー。 7.該非天然のアミノ酸配列が、細胞受容体結合配列または二重特異的もしくは 多重特異的蛋白結合配列である、請求の範囲6の短シャフトアデノウイルスファ イバー。 8.該非天然のアミノ酸配列が、該ノブの露出したループの天然アミノ酸配列の 中にまたはそれに代えて挿入されるか、あるいは該ノブのC末端の延長である、 請求の範囲6または7の短シャフトアデノウイルスファイバー。 9.該非天然のアミノ酸配列が、該短シャフトアデノウイルスファイバーを含む アデノウイルスのアッセンブリを妨げない、請求の範囲6〜8のいずれかの短シ ャフトアデノウイルスファイバー。 10.該短シャフトアデノウイルス蛋白が、いかなるウイルスからも離れている ときは同種のアデノウイルス受容体に結合するが、血清型5のアデノウイルスに 組み込まれたときは同種のアデノウイルス受容体に実質的に結合しない、請求の 範囲1〜9のいずれかの短シャフトアデノウイルスファイバー(但し、該血清型 5アデノウイルスは該短シャフトファイバーが組み込まれている以外は野生型ウ イルスである)。 11.請求の範囲1〜10のいずれかの短シャフトアデノウイルスファイバーを コードするDNAを含む導入ベクター。 12.請求の範囲1〜10のいずれかの短シャフトアデノウイルスファイバーを コードする短シャフトアデノウイルスファイバー遺伝子を含むバキュロウイルス 。 13.非天然の遺伝子および請求の範囲1〜10のいずれかの短シャフトアデノ ウイルスファイバーを含むアデノウイルス。 14.該アデノウイルスが組換えペントンベース蛋白をさらに含み、且つ該組換 えペントンベース蛋白が非天然のアミノ酸配列を含む、請求の範囲13のアデノ ウイルス。 15.該組換えペントンベース蛋白の該非天然のアミノ酸配列が、細胞受容体結 合配列、二重特異的または多重特異的蛋白結合配列である、請求の範囲14のア デノウイルス。 16.該アデノウイルスが、細胞結合を命令するペントンベース蛋白を含む、請 求の範囲13〜15のいずれかのアデノウイルス。 17.該アデノウイルスが細胞に結合し、該アデノウイルスと該細胞との該結合 が、いかなるアデノウイルスにも結合されず且つ該アデノウイルスの該短シャフ トファイバー蛋白と同一である短シャフトファイバーの存在下で、実質的に減少 しない、請求の範囲13〜16のいずれかのアデノウイルス。 18.該アデノウイルスが細胞に結合し、該アデノウイルスと細胞との該結合が 、いかなるアデノウイルスにも結合されず且つ該アデノウイルスの該短シャフト ファイバー蛋白と同一である短シャフトファイバーの存在下で、5%以下しか減 少しない、請求の範囲13〜16のいずれかのアデノウイルス。 19.該アデノウイルスが細胞に結合し、該アデノウイルスと該細胞との該結合 が、いかなるアデノウイルスにも結合されず且つ該アデノウイルスの該短シャフ トファイバー蛋白と同一である、1000倍モル過剰(遊離蛋白:ウイルス結合 蛋白)の短シャフトファイバーの存在下で、10%以下しか減少しない、請求の 範囲13〜16のいずれかのアデノウイルス。 20.該細胞が、該短シャフトファイバーがウイルスから離れているときには該 ファイバーが結合する細胞表面受容体を含まないものである、請求の範囲18〜 20のアデノウイルス。 21.該アデノウイルスが、非C群アデノウイルスを中和するがC群アデノウイ ルスを中和しない抗体によっては中和されないものである、請求の範囲13〜2 0のいずれかのアデノウイルス。 22.該アデノウイルスがC血清群のものである請求の範囲13〜20のいずれ かのアデノウイルス。 23.アデノウイルスの細胞への接着をターゲッティングしてアデノウイルスの 細胞侵入をもたらす方法であって、該細胞に請求の範囲13〜22のいずれかの アデノウイルスを接触させることを含む方法。 24.請求の範囲13〜22のいずれかのアデノウイルスの接着をターゲッティ ングする方法であって、 (a) 該アデノウイルスに二重特異的または多重特異的結合剤(該結合剤は、(i )該アデノウイルスの非天然アミノ酸配列と選択的に結合する第一成分および(ii )該細胞上の細胞表面結合部位と選択的に結合する第二成分を含む)を接触させて 、該アデノウイルスと該結合剤の複合体を形成させ、 (b) 該細胞への該アデノウイルスの侵入をもたらすように、該細胞に(a)の該 複合体を接触させること を含む方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/700,846 US5962311A (en) | 1994-09-08 | 1996-08-21 | Short-shafted adenoviral fiber and its use |
US08/700,846 | 1996-08-21 | ||
PCT/US1997/014718 WO1998007877A1 (en) | 1996-08-21 | 1997-08-21 | A short-shafted adenoviral fiber and its use |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2000516098A true JP2000516098A (ja) | 2000-12-05 |
Family
ID=24815119
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP10510960A Ceased JP2000516098A (ja) | 1996-08-21 | 1997-08-21 | 短シャフトアデノウイルスファイバーおよびその用途 |
Country Status (8)
Country | Link |
---|---|
US (1) | US5962311A (ja) |
EP (1) | EP0920524B1 (ja) |
JP (1) | JP2000516098A (ja) |
AT (1) | ATE313640T1 (ja) |
AU (1) | AU734515B2 (ja) |
CA (1) | CA2263189A1 (ja) |
DE (1) | DE69734930T2 (ja) |
WO (1) | WO1998007877A1 (ja) |
Families Citing this family (73)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5846782A (en) * | 1995-11-28 | 1998-12-08 | Genvec, Inc. | Targeting adenovirus with use of constrained peptide motifs |
US20020193580A1 (en) * | 1995-12-15 | 2002-12-19 | Mitchell Lloyd G. | Methods and compositions for use in spliceosome mediated RNA trans-splicing |
US20030027250A1 (en) * | 1995-12-15 | 2003-02-06 | Mitchell Lloyd G. | Methods and compositions for use in spliceosome mediated RNA trans-splicing |
US20060088938A1 (en) * | 1995-12-15 | 2006-04-27 | Mitchell Lloyd G | Methods and compositions for use in spliceosome mediated RNA trans-splicing in plants |
HUP0200073A3 (en) * | 1998-08-27 | 2003-12-29 | Aventis Pharma Sa | Targeted adenovirus vectors for delivery of heterologous genes |
US20050063950A1 (en) * | 1998-11-19 | 2005-03-24 | Georgetown University | Systemic viral/ligand gene delivery system and gene therapy |
US6303362B1 (en) | 1998-11-19 | 2001-10-16 | The Board Of Trustees Of The Leland Stanford Junior University | Adenoviral vector and methods for making and using the same |
DE60031994T2 (de) * | 1999-09-24 | 2007-09-20 | The Uab Research Foundation, Birmingham | Kapsidmodifiziertes rekombinantes Adenovirus und Verfahren zu dessen Anwendung |
SE9904289D0 (sv) * | 1999-11-26 | 1999-11-26 | Niklas Arnberg | Method and camposition for the treatment of adenovairal ocular infections |
US7653769B2 (en) * | 2006-12-14 | 2010-01-26 | International Business Machines Corporation | Management of devices connected to infiniband ports |
US6821775B1 (en) * | 2000-02-11 | 2004-11-23 | Genvec, Inc. | Viral vector encoding pigment epithelium-derived factor |
US7754201B2 (en) * | 2000-06-02 | 2010-07-13 | GenPhar, Inc | Method of vaccination through serotype rotation |
US6573092B1 (en) * | 2000-10-10 | 2003-06-03 | Genvec, Inc. | Method of preparing a eukaryotic viral vector |
US20040126774A1 (en) * | 2001-01-08 | 2004-07-01 | Mitchell Lioyd G. | Correction of factor VIII genetic defects using spliceosome mediated RNA trans splicing |
CA2445626A1 (en) * | 2001-04-17 | 2002-10-24 | Vectorlogics, Inc. | Mosaic adenoviral vectors |
US20060275262A1 (en) * | 2001-07-26 | 2006-12-07 | Mathis James M | Conditionally replicating viruses and methods for cancer virotherapy |
US7247297B2 (en) * | 2001-09-14 | 2007-07-24 | The University Of Chicago | Use of DF3/MUC1 regulated expression in gene therapy |
EP1427816A4 (en) | 2001-09-18 | 2004-12-01 | Clontech Lab Inc | METHOD FOR PRODUCING ADENOVIRAL VECTORS BASED ON A SITE SPECIFIC RECOMBINASE |
US20030158112A1 (en) * | 2002-02-15 | 2003-08-21 | Johns Hopkins University School Of Medicine | Selective induction of apoptosis to treat ocular disease |
US7399753B2 (en) * | 2002-02-25 | 2008-07-15 | Virxsys Corporation | Trans-splicing mediated photodynamic therapy |
US7094399B2 (en) * | 2002-05-08 | 2006-08-22 | Intronn, Inc. | Use of spliceosome mediated RNA trans-splicing to confer cell selective replication to adenoviruses |
CA2493254A1 (en) * | 2002-07-22 | 2004-01-29 | Vectorlogics, Inc. | Targeted adenoviral vector displaying immunoglobulin-binding domain and uses thereof |
WO2004038380A2 (en) * | 2002-10-23 | 2004-05-06 | Intronn, Inc. | Screening methods for identification of efficient pre-trans-splicing molecules |
CA2507036A1 (en) * | 2002-12-02 | 2004-06-17 | Genvec, Inc. | Materials and methods for treating ocular-related disorders |
US20040166091A1 (en) * | 2003-02-24 | 2004-08-26 | Genvec, Inc. | Materials and methods for treating disorders of the ear |
US20070275915A1 (en) * | 2003-04-15 | 2007-11-29 | Cell Genesys, Inc. | Tmprss2 Regulatory Sequences and Uses Thereof |
US20070212675A1 (en) * | 2003-04-15 | 2007-09-13 | Novartis Ag | Flap Endonuclease (Fen1) Regulatory Sequences And Uses Thereof |
EP1649028B1 (en) * | 2003-07-25 | 2012-08-22 | Genvec, Inc. | Adenoviral vector-based vaccines |
WO2005024032A2 (en) * | 2003-09-03 | 2005-03-17 | Vectorlogics, Inc. | Targeting adenoviral vectors to dendritic cells |
JP2007511507A (ja) * | 2003-11-14 | 2007-05-10 | ジェンベク、インコーポレイティッド | 癌を処置するための治療レジメン |
US7968334B2 (en) * | 2004-01-23 | 2011-06-28 | Virxsys Corporation | Expression of apoAI and variants thereof using spliceosome mediated RNA trans-splicing |
JP2007518423A (ja) * | 2004-01-23 | 2007-07-12 | イントロン、インコーポレイテッド | スプライセオソーム仲介型rnaトランススプライシングを使用するアポa−1及びその変異体の発現 |
US8053232B2 (en) * | 2004-01-23 | 2011-11-08 | Virxsys Corporation | Correction of alpha-1-antitrypsin genetic defects using spliceosome mediated RNA trans splicing |
WO2005089811A1 (en) * | 2004-03-12 | 2005-09-29 | Genvec, Inc. | Materials for treating vascular leakage in the eye |
US7473418B2 (en) * | 2004-03-25 | 2009-01-06 | Cell Genesys, Inc. | Pan cancer oncolytic vectors and methods of use thereof |
US20070207166A1 (en) | 2004-04-12 | 2007-09-06 | Genvec, Inc. | Method of Using Adenoviral Vectors to Induce an Immune Response |
US20060094110A1 (en) * | 2004-07-30 | 2006-05-04 | Mcgarrity Gerard J | Use of spliceosome mediated RNA trans-splicing for immunotherapy |
US20060134658A1 (en) * | 2004-08-09 | 2006-06-22 | Garcia-Blanco Mariano A | Use of RNA trans-splicing for generation of interfering RNA molecules |
US20060062764A1 (en) * | 2004-08-25 | 2006-03-23 | Seshidar-Reddy Police | Fiber-modified adenoviral vectors for enhanced transduction of tumor cells |
EP1784493A2 (en) * | 2004-09-01 | 2007-05-16 | The Government of the United States of America as Represented by The Department of Health and Human Services | Adenoviral vectors able to transduce apcs, potential use in immune response generation |
DE102004047492B4 (de) * | 2004-09-23 | 2006-07-20 | Jost-Werke Gmbh & Co. Kg | Verfahren zum Übertragen von elektrischer, pneumatischer oder hydraulischer Energie sowie ein Energieübertragungssystem |
AU2005326784B2 (en) * | 2004-10-08 | 2012-03-15 | Virxsys Corporation | Use of RNA trans-splicing for antibody gene transfer and antibody polypeptide production |
US7871795B2 (en) | 2004-10-08 | 2011-01-18 | Virxsys Corporation | Targeted trans-splicing of highly abundant transcripts for in vivo production of recombinant proteins |
US20060188481A1 (en) * | 2005-02-22 | 2006-08-24 | Saitama Medical School | Methods for prophylactically or therapeutically treating an animal for an ocular-related disorder |
US20060234347A1 (en) * | 2005-04-13 | 2006-10-19 | Harding Thomas C | Targeting multiple angiogenic pathways for cancer therapy using soluble tyrosine kinase receptors |
US8450055B2 (en) * | 2005-08-31 | 2013-05-28 | The United States Of America As Represented By The Secretary Of The Navy | Malaria antigen screening method |
US9651543B2 (en) | 2005-08-31 | 2017-05-16 | The United States Of America As Represented By The Secretary Of The Navy | Malaria antigen screening method |
AU2006284756B2 (en) * | 2005-08-31 | 2012-06-07 | Genvec, Inc. | Adenoviral vector-based malaria vaccines |
WO2007059461A2 (en) * | 2005-11-10 | 2007-05-24 | Genvec, Inc. | Adenoviral vector-based foot-and-mouth disease vaccine |
EP2025762A3 (en) | 2006-01-17 | 2009-09-30 | Health Research Inc. | Heteroduplex tracking assay |
ES2363891T3 (es) | 2006-03-20 | 2011-08-18 | The Regents Of The University Of California | Anticuerpos contra el antígeno de células troncales de la próstata (psca) modificados genéticamente para el direccionamiento al cáncer. |
US20100278870A1 (en) * | 2007-01-09 | 2010-11-04 | The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. | Adenoviral vector-based malaria vaccines |
WO2009032949A2 (en) | 2007-09-04 | 2009-03-12 | The Regents Of The University Of California | High affinity anti-prostate stem cell antigen (psca) antibodies for cancer targeting and detection |
US20090202492A1 (en) * | 2008-01-25 | 2009-08-13 | University Of South Florida | Adenovirus vaccine utilizing ikk as adjuvant |
US9605844B2 (en) * | 2009-09-01 | 2017-03-28 | Cree, Inc. | Lighting device with heat dissipation elements |
US20120219583A1 (en) | 2009-10-16 | 2012-08-30 | Los Alamos National Security, Llc | Nucleic acid sequences encoding expandable hiv mosaic proteins |
EP2853266B1 (en) | 2009-11-09 | 2018-01-31 | Genvec, Inc. | Method of propagating monkey adenoviral vectors |
WO2011057254A2 (en) | 2009-11-09 | 2011-05-12 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Simian adenoviral vector-based vaccines |
EP2547362B1 (en) | 2010-03-17 | 2021-08-25 | Cornell University | Disrupted adenovirus-based vaccine against drugs of abuse |
CN103038343A (zh) | 2010-03-23 | 2013-04-10 | 英特瑞克斯顿股份有限公司 | 条件表达治疗蛋白的载体,包含所述载体的宿主细胞,及其应用 |
WO2012021730A2 (en) | 2010-08-11 | 2012-02-16 | Genvec, Inc. | Respiratory syncytial virus (rsv) vaccine |
WO2012083297A2 (en) | 2010-12-17 | 2012-06-21 | Genvec, Inc. | Adenoviral vectors with modified hexon regions |
WO2012088041A1 (en) | 2010-12-20 | 2012-06-28 | Genvec, Inc. | Adenoviral vector-based dengue fever vaccine |
SG10201600912SA (en) | 2011-03-04 | 2016-03-30 | Intrexon Corp | Vectors conditionally expressing protein |
WO2013090806A2 (en) * | 2011-12-15 | 2013-06-20 | Washington University | Porcine knob xenotype chimeric adenoviral vector for dendritic cell infection |
WO2013181128A1 (en) | 2012-05-29 | 2013-12-05 | Genvec, Inc. | Modified serotype 28 adenoviral vectors |
CA3115891A1 (en) | 2013-03-14 | 2014-09-25 | Salk Institute For Biological Studies | Oncolytic adenovirus compositions |
TWI710635B (zh) | 2014-10-09 | 2020-11-21 | 美商珍維克公司 | 編碼人類無調同源物-1(hath1)之腺病毒載體 |
EP3390428B1 (en) | 2016-02-23 | 2019-09-25 | Salk Institute for Biological Studies | High throughput assay for measuring adenovirus replication kinetics |
CN108699566B (zh) | 2016-02-23 | 2023-06-30 | 萨克生物研究学院 | 对病毒动力学影响最小的治疗性腺病毒中的外源基因表达 |
CA3038968A1 (en) | 2016-09-30 | 2018-04-05 | Genvec, Inc. | Adenovectors for delivery of therapeutic genetic material into t cells |
AU2017375633C1 (en) | 2016-12-12 | 2023-04-27 | Salk Institute For Biological Studies | Tumor-targeting synthetic adenoviruses and uses thereof |
CN113710810A (zh) | 2019-02-21 | 2021-11-26 | 安利舒免疫溶瘤技术公司 | 溶瘤腺病毒载体和使用方法 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4593002A (en) * | 1982-01-11 | 1986-06-03 | Salk Institute Biotechnology/Industrial Associates, Inc. | Viruses with recombinant surface proteins |
US5223409A (en) * | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
US5521291A (en) * | 1991-09-30 | 1996-05-28 | Boehringer Ingelheim International, Gmbh | Conjugates for introducing nucleic acid into higher eucaryotic cells |
NZ244306A (en) * | 1991-09-30 | 1995-07-26 | Boehringer Ingelheim Int | Composition for introducing nucleic acid complexes into eucaryotic cells, complex containing nucleic acid and endosomolytic agent, peptide with endosomolytic domain and nucleic acid binding domain and preparation |
GB9223084D0 (en) * | 1992-11-04 | 1992-12-16 | Imp Cancer Res Tech | Compounds to target cells |
US5543328A (en) * | 1993-08-13 | 1996-08-06 | Genetic Therapy, Inc. | Adenoviruses having modified fiber proteins |
FR2714264A1 (fr) * | 1993-12-29 | 1995-06-30 | Maurice Fradin | Procédé pour la préparation de pains de viande ou analogue, utilisables pour la fabrication de viande feuilletée. |
US6312699B1 (en) * | 1994-03-28 | 2001-11-06 | Uab Research Foundation | Ligands added to adenovirus fiber |
US5559099A (en) * | 1994-09-08 | 1996-09-24 | Genvec, Inc. | Penton base protein and methods of using same |
PL327038A1 (en) * | 1995-11-28 | 1998-11-09 | Genvec Inc | Vectors for and methods of transferring genes into cells |
-
1996
- 1996-08-21 US US08/700,846 patent/US5962311A/en not_active Expired - Lifetime
-
1997
- 1997-08-21 DE DE69734930T patent/DE69734930T2/de not_active Expired - Fee Related
- 1997-08-21 AT AT97939477T patent/ATE313640T1/de not_active IP Right Cessation
- 1997-08-21 EP EP97939477A patent/EP0920524B1/en not_active Expired - Lifetime
- 1997-08-21 JP JP10510960A patent/JP2000516098A/ja not_active Ceased
- 1997-08-21 CA CA002263189A patent/CA2263189A1/en not_active Abandoned
- 1997-08-21 AU AU41555/97A patent/AU734515B2/en not_active Ceased
- 1997-08-21 WO PCT/US1997/014718 patent/WO1998007877A1/en active IP Right Grant
Also Published As
Publication number | Publication date |
---|---|
EP0920524B1 (en) | 2005-12-21 |
AU4155597A (en) | 1998-03-06 |
DE69734930T2 (de) | 2006-08-24 |
WO1998007877A1 (en) | 1998-02-26 |
AU734515B2 (en) | 2001-06-14 |
ATE313640T1 (de) | 2006-01-15 |
US5962311A (en) | 1999-10-05 |
CA2263189A1 (en) | 1998-02-26 |
EP0920524A1 (en) | 1999-06-09 |
DE69734930D1 (de) | 2006-01-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2000516098A (ja) | 短シャフトアデノウイルスファイバーおよびその用途 | |
US5712136A (en) | Adenoviral-mediated cell targeting commanded by the adenovirus penton base protein | |
US5770442A (en) | Chimeric adenoviral fiber protein and methods of using same | |
US6225113B1 (en) | Use of trans-activation and cis-activation to modulate the persistence of expression of a transgene in an at least E4-deficient adenovirus | |
US6455314B1 (en) | Alternatively targeted adenovirus | |
US5846782A (en) | Targeting adenovirus with use of constrained peptide motifs | |
AU745252B2 (en) | Chimeric adenoviral coat protein and methods of using same | |
CA2236912C (en) | Vectors and methods for gene transfer to cells | |
ES2246533T3 (es) | Fibra adenovirica modificada y adenovirus dianas. | |
AU2002344190B2 (en) | Adenovirus protein IX, Its domains involved in capsid assembly, transcriptional activity and nuclear reorganization | |
CA2318492C (en) | Gene delivery vectors provided with a tissue tropism for smooth muscle cells, and/or endothelial cells |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20040723 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20070619 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20070919 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20071029 |
|
A313 | Final decision of rejection without a dissenting response from the applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A313 Effective date: 20080130 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20080311 |